Positive efficacy and safety data of MaaT013 in aGvHD in the Early Access Program presented at the EBMT 2024 annual meeting with 63% GI-ORR at D28, a 49% one year and 42% 18 months Overall...
Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers Regulatory News: MaaT Pharma (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé...
Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to...
Article 223-16 of the General Regulations of the Financial Markets Authority (AMF - Autorité des Marchés Financiers) Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a...
Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers Regulatory News: MaaT Pharma (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.08 | 1.10192837466 | 7.26 | 7.34 | 7.04 | 267 | 7.24649701 | DE |
4 | 0.28 | 3.96600566572 | 7.06 | 7.4 | 7 | 380 | 7.26573531 | DE |
12 | -0.18 | -2.39361702128 | 7.52 | 8.14 | 7 | 858 | 7.50994423 | DE |
26 | -1.96 | -21.0752688172 | 9.3 | 9.9 | 6.52 | 1470 | 8.05563124 | DE |
52 | 0.96 | 15.0470219436 | 6.38 | 9.9 | 4.5 | 1605 | 7.4642616 | DE |
156 | -6.16 | -45.6296296296 | 13.5 | 14.4 | 4.5 | 1295 | 9.4505976 | DE |
260 | -6.16 | -45.6296296296 | 13.5 | 14.4 | 4.5 | 1295 | 9.4505976 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.